• OUR RESEARCH
    • NASH
    • Targets & Clinical Progress
    • Posters/Publications
  • OUR PIPELINE
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • OUR STORY
    • Overview
    • Management Team
    • Partnership
  • NEWS
  • CAREERS

OUR RESEARCH

  • NASH
  • Targets & Clinical Progress
  • Posters/Publications

OUR PIPELINE

  • Pipeline
  • Clinical Trials
  • Expanded Access Policy

OUR STORY

  • Overview
  • Management Team
  • Partnership

NEWS

CAREERS

Posters/Publications

  • Title
  • Venue
  • Type
  • Date
  • ASC43F Tablet as a One pill, Once a day Fixed dose Combination of ASC41 a THR-β Agonist, and ASC42 a FXR Agonist, Demonstrated Comparable Dissolution Profiles and in vivo Pharmacokinetics VS Single ASC41 and ASC42 Tablets
    The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD)
    Poster
    11/2021
  • ASC42, a Novel Non-steroidal FXR Agonist, Demonstrates a Normal Cholesterol Profile and Lack of Pruritus at Therapeutic Doses in a 14-day Phase I Randomized, Double-blind, Placebo Controlled Study in Healthy Volunteers
    The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD)
    Poster
    11/2021
  • A Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC 41 a THR-β Agonist, for 28-days in Overweight and Obese Subjects with Elevated LDL-C, a Population with Characteristic s Of NAFLD
    The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD)
    Poster
    11/2021
FIND US:

All contents © Copyright Gannex Pharma Co., Ltd.All Rights Reserved

This site is published by Gannex Pharma Co., Ltd.

which is solely responsible for all site content.